While MannKind Corporation (NASDAQ:MNKD) plunged about 32% over the past five sessions — as the Food and Drug Administration (FDA) investigated the company’s inhaled diabetes drug Afrezza — the shares have spiked 88% out of yesterday’s gate to perch at $7.43, on news that an FDA advisory panel voted in favor of the medication. MannKind Corporation (NASDAQ:MNKD) shares after opening at $7.75 on last trade day and at the end of the day closed at $6.99. Company price to cash ratio in past twelve months was calculated as 37.24. MannKind Corporation (NASDAQ:MNKD)showed a positive weekly performance of 20.52%.
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, announced that it will have two poster presentations at the 2014 American Association for Cancer Research (AACR) Annual Meeting. The conference will take place in San Diego, California, on April 5-9, 2014 at the San Diego Convention Center. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) shares advanced 12.28% in last trading session and ended the day on $1.28. RNN return on equity ratio is recorded as -81.70% and its return on assets is -49.00%. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) yearly performance is 300.00%.
HAGENS BERMAN REMINDS CYTRX INVESTORS OF MAY 13, 2014 LEAD PLAINTIFF DEADLINE AND CONTINUED SECURITIES FRAUD INVESTIGATION .Hagens Berman Sobol Shapiro LLP, reminds investors of the May 13, 2014 deadline to file for lead plaintiff in the securities fraud class action against CytRx Corporation (NASDAQ:CYTR).CytRx Corporation(NASDAQ:CYTR) shares moved up 6.13% in last trading session and was closed at $3.81, while trading in range of $3.56 – $3.84. CytRx Corporation (NASDAQ:CYTR) year to date (YTD) performance is -39.23%.
Cerus Corp. (NASDAQ:CERS) was upgraded by analysts at Thomson Reuters/Verus from a sell rating to a hold rating. Cerus Corporation (NASDAQ:CERS) weekly performance is 5.71%. On last trading day company shares ended up $5.18. Cerus Corporation(NASDAQ:CERS) distance from 50-day simple moving average (SMA50) is -17.31%. Analysts mean target price for the company is $8.50.